2023年4月24日

公司增加了多個醫療行業領導人顧問委員會3月16日,2022(佛蒙特州的伯靈頓)——Biocogniv數字診斷公司專注於預測時序要求嚴格的醫療條件使用人工智能(AI)的實驗室數據,今天宣布關閉6美元滾滾種子輪由布雷耶資本,在Y Combinator的參與下,1984年企業,改變健康、Promus投資,該基金在草裙舞,以及幾個著名天使投資人,包括波士頓科技公司的創始人約翰銀白楊,IBM的前首席執行官彭明盛LabCorp前執行副總裁CMO和全封閉Myla Lai-Goldman, MD,佩奇。艾未未的前首席執行官利奧格雷迪博士和Syapse的創始人和前總統喬納森·赫希。作為此輪融資的一部分,Myla Lai-Goldman,利奧格雷迪,和喬納森·赫希也將加入Biocogniv的顧問委員會。“在醫院,每小時的延遲保健可能導致長期發病率和,在某些情況下,死亡。例如與膿毒症——在美國住院死亡的主要原因,推遲或不恰當的護理有相當於前列腺癌死亡率負擔,造成每年有超過30000的美國人,“說Biocogniv首席執行官、前美國國立衛生研究院的教員,阿圖爾阿迪,博士學位。“在Biocogniv,我們推進急症護理成為未來,大多數的死亡是避免,利用最先進的人工智能實驗室數據。我們的新投資者的口徑和顧問證明了這項工作的重要性。“使用真實的實驗室數據從數以百計的醫院和戰略合作夥伴,Biocogniv創造了aiMarkers™,人工智能預測模型,可以檢測急性條件之前就變得不可逆轉,和傾斜™,實時,基於雲計算平台,部署這些模型在臨床護理。該公司將使用新的資金進一步發展和驗證其aiMarkers™和傾斜™平台。“aiMarkers™是另一個例子醫療的AI的尚未開發的潛力。Biocogniv敏捷團隊一直解決困難的問題參與將這一創新臨床實踐,吸引關鍵行業合作夥伴和思想領袖。 As long-term believers in the disruptive power of AI in healthcare, we couldn’t be more excited to join forces with them,” said venture capital pioneer Jim Breyer, founder and CEO of Breyer Capital. “Many companies are building AI for patient care, often without the proper rigor and clinical validation required for broad adoption in medicine,” said Leo Grady, PhD, CEO-in-Residence at Breyer Capital, who spearheaded the first FDA approval for an AI product in pathology as CEO of Paige.AI. “I am impressed with the results and progress that Biocogniv was able to achieve in a short period of time and I look forward to helping the company in this next phase.” About Breyer Capital Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the US and China. Founded by legendary investor Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in artificial intelligence, digital health, data analytics, social media, and financial technologies. The firm prides itself on maintaining an openness to experimentation that can lead to long-term breakthrough performance and partnering with founders and teams who are passionate about building transformative companies anchored in technology. For more information, please visit http://www.breyercapital.com . About Biocogniv Biocogniv is the world’s first digital diagnostic company tackling time-critical conditions using artificial intelligence on top of laboratory data. The company’s software platform, clinOS™, is already connected to multiple hospital systems across the US, processing thousands of laboratory tests per day, and its pipeline of aiMarkers™ includes predictors for sepsis, respiratory failure, acute heart failure, and others. For more information, please visit http://www.biocogniv.com . Address: